Firms To Be Held More Accountable For Completing Postmarket Studies – FDA
This article was originally published in The Gray Sheet
Executive Summary
FDA plans to shift the tracking of postmarket studies from the Office of Device Evaluation to the Office of Surveillance & Biometrics by year-end to enable ODE to better meet MDUFMA goals
You may also be interested in...
Industry Reps Cite Pitfalls In FDA’s New Approach To Postapproval Studies
The recent shift of responsibility for device condition-of-approval studies to the FDA's Office of Surveillance & Biometrics could result in more elaborate and burdensome study requirements if device firms are not careful, speakers warned at this year's Regulatory Affairs Professionals Society annual meeting
Industry Reps Cite Pitfalls In FDA’s New Approach To Postapproval Studies
The recent shift of responsibility for device condition-of-approval studies to the FDA's Office of Surveillance & Biometrics could result in more elaborate and burdensome study requirements if device firms are not careful, speakers warned at this year's Regulatory Affairs Professionals Society annual meeting
AdvaMed To FDA: IRB Uncertainty, Trial Recruiting Hamper CoA Studies
Institutional review board confusion over FDA condition-of-approval (CoA) study requirements is a barrier to completing such studies, according to AdvaMed